During the last session, Humacyte Inc (NASDAQ:HUMA)’s traded shares were 3.62 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $5.05, reflecting an intraday loss of -1.94% or -$0.1. The 52-week high for the HUMA share is $9.97, that puts it down -97.43 from that peak though still a striking 61.19% gain since the share price plummeted to a 52-week low of $1.96. The company’s market capitalization is $632.31M, and the average intraday trading volume over the past 10 days was 2.99 million shares, and the average trade volume was 3.02 million shares over the past three months.
Humacyte Inc (HUMA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. HUMA has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ:HUMA) trade information
Humacyte Inc (HUMA) registered a -1.94% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.94% in intraday trading to $5.05, hitting a weekly high. The stock’s 5-day price performance is -13.23%, and it has moved by -11.25% in 30 days. Based on these gigs, the overall price performance for the year is 138.21%. The short interest in Humacyte Inc (NASDAQ:HUMA) is 16.68 million shares and it means that shorts have 6.18 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 15.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $10 respectively. As a result, HUMA is trading at a discount of -98.02% off the target high and 0.99% off the low.
Humacyte Inc (HUMA) estimates and forecasts
Statistics show that Humacyte Inc has underperformed its competitors in share price, compared to the industry in which it operates. Humacyte Inc (HUMA) shares have gone up 14.77% during the last six months, with a year-to-date growth rate less than the industry average at -1.87% against 17.30.
Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 420k by the end of current fiscal year.
While earnings are projected to return -12.91% in 2024.
HUMA Dividends
Humacyte Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Humacyte Inc insiders own 27.91% of total outstanding shares while institutional holders control 25.61%, with the float percentage being 35.53%. BLACKROCK INC. is the largest shareholder of the company, while 175.0 institutions own stock in it. As of 2024-06-30, the company held over 7.14 million shares (or 6.5961% of all shares), a total value of $34.27 million in shares.
The next largest institutional holding, with 4.73 million shares, is of VANGUARD GROUP INC’s that is approximately 4.3693% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.7 million.
